Anti–monocyte chemoattractant protein-1/monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries

Y Furukawa, A Matsumori, N Ohashi, T Shioi… - Circulation …, 1999 - Am Heart Assoc
Y Furukawa, A Matsumori, N Ohashi, T Shioi, K Ono, A Harada, K Matsushima, S Sasayama
Circulation research, 1999Am Heart Assoc
Monocyte chemoattractant protein-1 (MCP-1)/monocyte chemotactic and activating factor
(MCAF) has been suggested to promote atherogenesis. The effects of in vivo neutralization
of MCP-1 in a rat model were examined in an effort to clarify the role of MCP-1 in the
development of neointimal hyperplasia. Competitive polymerase chain reaction analysis
revealed maximum MCP-1 mRNA expression at 4 hours after carotid arterial injury.
Increased immunoreactivities of MCP-1 were also detected at 2 and 8 hours after injury …
Abstract
—Monocyte chemoattractant protein-1 (MCP-1)/monocyte chemotactic and activating factor (MCAF) has been suggested to promote atherogenesis. The effects of in vivo neutralization of MCP-1 in a rat model were examined in an effort to clarify the role of MCP-1 in the development of neointimal hyperplasia. Competitive polymerase chain reaction analysis revealed maximum MCP-1 mRNA expression at 4 hours after carotid arterial injury. Increased immunoreactivities of MCP-1 were also detected at 2 and 8 hours after injury. Either anti–MCP-1 antibody or nonimmunized goat IgG (10 mg/kg) was then administered every 12 hours to rats that had undergone carotid arterial injury. Treatment with 3 consecutive doses of anti–MCP-1 antibody within 24 hours (experiment 1) and every 12 hours for 5 days (experiment 2) significantly inhibited neointimal hyperplasia at day 14, resulting in a 27.8% reduction of the mean intima/media ratio (P<0.05) in experiment 1 and a 43.6% reduction (P<0.01) in experiment 2. This effect was still apparent at day 56 (55.6% inhibition; P<0.05). The number of vascular smooth muscle cells in the neointima at day 4 was significantly reduced by anti–MCP-1 treatment, demonstrating the important role of MCP-1 in early neointimal lesion formation. However, recombinant MCP-1 did not stimulate chemotaxis of vascular smooth muscle cells in an in vitro migration assay. These results suggest that MCP-1 promotes neointimal hyperplasia in early neointimal lesion formation and that neutralization of MCP-1 before, and immediately after, arterial injury may be effective in preventing restenosis after angioplasty. Further studies are needed to clarify the mechanism underlying the promotion of neointimal hyperplasia by MCP-1.
Am Heart Assoc